BNTX:NASDAQ
BioNTech SE - ADR
96,85 US$
arrow_downward
-1,48%(-1,45) 1D
96,85 US$
0,00% (0,00)
bedtimeAfter hours
Closed: 1 ოქტ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
97,59 US$
High
99,49 US$
Low
96,60 US$
Mkt. cap
24,33 მლრდ.
Avg. vol.
1,46 მლნ.
Volume
0,00
52-wk high
123,98 US$
52-wk low
79,52 US$
EPS
-7,60 US$
Beta
1,27
Shares outstanding
251,20 მლნ.
No. of employees
8 ათ.
Open
97,59 US$
High
99,49 US$
Low
96,60 US$
Mkt. cap
24,33 მლრდ.
Avg. vol.
1,46 მლნ.
Volume
0,00
52-wk high
123,98 US$
52-wk low
79,52 US$
EPS
-7,60 US$
Beta
1,27
Shares outstanding
251,20 მლნ.
No. of employees
8 ათ.
News stories
From web sources and news partners
AD HOC NEWS
·
14 საათის წინ
BioNTech stock after-hours at EUR 87.00: plus 0.29 percent
AD HOC NEWS
·
1 დღის წინ
BioNTech's Founders Are Building a New mRNA Company While Their Old One Shrinks to a Cancer Lab
Zacks Investment Research
·
1 დღის წინ
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?
Zacks
·
1 დღის წინ
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR